Dr Eliot Forster, Chairman of Avacta Group, commented:
“I am delighted that Dr Williams is joining Avacta and very much look forward to working with him. Sam has extensive experience of the Biotech industry both as an investor and operator which he will bring to the Board.”
Avacta Group plc (LON: AVCT), the developer of Affimer® biotherapeutics and reagents, today announced the appointment of Dr Sam Williams as Non-Executive Director to the Board with immediate effect.
Dr Williams is currently Managing Partner and Head of Life Sciences at IP Group plc, the FTSE 250 investor in Life Sciences and Technology. He has an outstanding track-record in the biotech sector, both as a top-ranked biotechnology analyst in the City whilst at Lehman Brothers and, subsequently, as a Director and CEO, in which capacity he has overseen the development of novel therapeutics through early-stage clinical testing and successfully negotiated global alliances with major pharmaceutical companies. Thus, he brings extensive financial, operational and investment expertise to the Avacta Board.
Dr Williams was awarded a PhD in Molecular Biology by Cambridge University, earned while working in the laboratory of Sir Greg Winter, Nobel Laureate, and has a degree in Biology from Oxford University.
